Get the Stockscreener App
10.50
1.94%
0.20
After Hours:
10.51
0.010
+0.10%
Astria Therapeutics Inc stock is traded at $10.50, with a volume of 156.19K.
It is up +1.94% in the last 24 hours and down -8.46% over the past month.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.
See More
Previous Close:
$10.30
Open:
$10.4
24h Volume:
156.19K
Relative Volume:
0.50
Market Cap:
$581.27M
Revenue:
-
Net Income/Loss:
$-72.89M
P/E Ratio:
-4.3033
EPS:
-2.44
Net Cash Flow:
$-68.47M
1W Performance:
+9.60%
1M Performance:
-8.46%
6M Performance:
+16.41%
1Y Performance:
+122.93%
1-Day Range:
$10.20
$10.64
1-Week Range:
$9.20
$10.64
52-Week Range:
$4.50
$16.90
Astria Therapeutics Inc Stock (ATXS) Company Profile
Name
Astria Therapeutics Inc
Sector
Industry
Phone
617-349-1971
Address
22 BOSTON WHARF ROAD, BOSTON
Compare ATXS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATXS
Astria Therapeutics Inc
|
10.50 | 581.27M | 0 | -72.89M | -68.47M | -2.44 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Astria Therapeutics Inc Stock (ATXS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-29-24 | Initiated | TD Cowen | Buy |
| Mar-28-23 | Initiated | Evercore ISI | Outperform |
Astria Therapeutics Inc Stock (ATXS) Latest News
Trend Tracker for (ATXS) - Stock Traders Daily
Astria Therapeutics: Transformative Proof Of Concept Data In Hereditary Angioedema - Seeking Alpha
Brokerages Set Astria Therapeutics, Inc. (NASDAQ:ATXS) Target Price at $25.60 - MarketBeat
Astria Therapeutics Reports Q3 2024 Financial Results - MSN
Equities Analysts Offer Predictions for ATXS FY2024 Earnings - MarketBeat
Astria Therapeutics’ (ATXS) Buy Rating Reiterated at HC Wainwright - Defense World
Astria Therapeutics (NASDAQ:ATXS) Price Target Raised to $28.00 - Defense World
Astria Therapeutics (NASDAQ:ATXS) Shares Down 5.3%What's Next? - MarketBeat
RA Capital Management, L.P. Expands Stake in Astria Therapeutics Inc - GuruFocus.com
Vestal Point Capital, LP Increases Stake in Astria Therapeutics Inc - GuruFocus.com
Oppenheimer Forecasts Strong Price Appreciation for Astria Therapeutics (NASDAQ:ATXS) Stock - MarketBeat
Astria Therapeutics (NASDAQ:ATXS) Shares Gap Up on Analyst Upgrade - MarketBeat
Companies Like Astria Therapeutics (NASDAQ:ATXS) Are In A Position To Invest In Growth - Simply Wall St
Astria's HAE Drug Shows 96% Attack Reduction; Phase 3 Set for Q1 2025 | ATXS Stock News - StockTitan
Astria Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Astria Therapeutics to Present at Upcoming Jefferies London Healthcare Conference - sharewise
FMR LLC Acquires Significant Stake in Astria Therapeutics Inc - GuruFocus.com
Astria Therapeutics (NASDAQ:ATXS) Stock Crosses Above 50-Day Moving AverageHere's Why - MarketBeat
How to Take Advantage of moves in (ATXS) - Stock Traders Daily
Vanguard Group Inc's Strategic Acquisition in Astria Therapeutics Inc - GuruFocus.com
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - XM
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StockTitan
Astria Therapeutics to Present at Upcoming Canadian Society of Allergy and Clinical Immunology Annual Scientific Meeting - Business Wire
Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives Average Rating of "Buy" from Analysts - MarketBeat
Objective long/short (ATXS) Report - Stock Traders Daily
Astria Therapeutics (NASDAQ:ATXS) Shares Up 6.8%Here's What Happened - MarketBeat
Astria Therapeutics (NASDAQ:ATXS) Share Price Crosses Below 50 Day Moving AverageHere's Why - MarketBeat
Astria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific Meeting - Business Wire
European Commission Grants Orphan Medicinal Product Designation for Navenibart, Astria Therapeutics’ Investigational Therapy for the Treatment of Hereditary Angioedema - BioSpace
Astria Therapeutics gains orphan drug status in EU for HAE treatment - Investing.com Australia
(ATXS) Trading Report - Stock Traders Daily
Astria Therapeutics, Inc. (NASDAQ:ATXS) Short Interest Update - MarketBeat
Astria Therapeutics, Inc. (NASDAQ:ATXS) Short Interest Down 9.2% in September - MarketBeat
Astria Therapeutics (NASDAQ:ATXS) Stock Price Down 4.1%Should You Sell? - MarketBeat
Renaissance Technologies LLC Decreases Stock Position in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
Dimensional Fund Advisors LP Buys 133,379 Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) - MarketBeat
Cubist Systematic Strategies LLC Purchases New Position in Astria Therapeutics, Inc. (NASDAQ:ATXS) - MarketBeat
Astria Therapeutics (NASDAQ:ATXS) Trading 5.2% HigherHere's What Happened - MarketBeat
Astria Therapeutics, Inc. (NASDAQ:ATXS) Shares Purchased by Millennium Management LLC - MarketBeat
Astria Therapeutics, Inc. (NASDAQ:ATXS) Given Average Rating of "Buy" by Analysts - MarketBeat
Insider Sale Alert: Astria Therapeutics Inc [ATXS] – Is it Time to sell? - Knox Daily
Nantahala Capital Management LLC Makes New $6.14 Million Investment in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
Are Astria Therapeutics Inc (ATXS) shares a good deal now? - US Post News
Closing Figures Unveiled: Astria Therapeutics Inc (ATXS) Drop -1.17, Closes at 11.01 - The Dwinnex
Logos Global Management LP Decreases Position in Astria Therapeutics, Inc. (NASDAQ:ATXS) - MarketBeat
ATXSAstria Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Astria Therapeutics Receives FDA Orphan Drug Designation for Navenibart (STAR-0215) for the Treatment of Hereditary Angioedema - StockTitan
Cubist Systematic Strategies LLC Invests $2.56 Million in Astria Therapeutics, Inc. (NASDAQ:ATXS) - MarketBeat
Astria Therapeutics Inc Stock (ATXS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Astria Therapeutics Inc Stock (ATXS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Morabito Christopher | Chief Medical Officer |
Apr 01 '24 |
Sale |
13.59 |
10,000 |
135,939 |
0 |
| PERCEPTIVE ADVISORS LLC | Director |
Feb 01 '24 |
Buy |
12.09 |
2,481,350 |
29,999,522 |
4,873,721 |
| Morabito Christopher | Chief Medical Officer |
Jan 29 '24 |
Option Exercise |
3.87 |
9,200 |
35,604 |
9,200 |
| Morabito Christopher | Chief Medical Officer |
Jan 26 '24 |
Option Exercise |
3.87 |
800 |
3,096 |
800 |
| Morabito Christopher | Chief Medical Officer |
Jan 29 '24 |
Sale |
11.15 |
9,200 |
102,552 |
0 |
| Morabito Christopher | Chief Medical Officer |
Jan 26 '24 |
Sale |
11.02 |
800 |
8,812 |
0 |
| PERCEPTIVE ADVISORS LLC | Director |
Dec 21 '23 |
Buy |
6.20 |
740,000 |
4,588,000 |
2,392,371 |
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):